The US FDA has accepted an amended investigational new drug application for the production and distribution of Radiopharm Theranostics' 68Ga-Trivehexin (RAD 301).
US FDA gives green light for Trivehexin diagnostic Phase 1 pancreatic clinical trial
October 18, 2023 Australian Biotech
Latest Video
New Stories
-
Weight loss medicines drive revenue sales growth for Sigma and Wesfarmers Health
August 28, 2026 - - BioPharma -
Patients Australia put healthcare’s quiet achievers in the spotlight
August 28, 2026 - - Latest News -
Cheaper medicines save Australians $1.4 billion as pharmacists urge freeze for all patients
August 28, 2026 - - Latest News -
Mayne Pharma bets on women’s health and direct distribution after a difficult year
August 28, 2026 - - Latest News -
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News -
Australian company secures Mitsubishi partnership to bring BioPQQ to market
August 26, 2026 - - Latest News -
Noxopharm pushes Sofra platform towards cancer proof of concept
August 26, 2026 - - Australian Biotech
